# Nanostructured Lipid Carriers Containing Acridine Derivatives in the Application of Sonodynamic Therapy for the Treatment of Breast Cancer

## TL;DR

This study explores using nanostructured lipid carriers with acridine derivatives for sonodynamic therapy to treat breast cancer, showing promising tumor inhibition.

## Contribution

The novelty lies in formulating and characterizing nanostructured lipid carriers with acridine derivatives for sonodynamic therapy in breast cancer treatment.

## Key findings

- NLC containing AMTAC 02 showed a tumor inhibition potential six times greater than the untreated group.
- AMTAC 02 generated the highest reactive oxygen species (ROS) at 282% in the SOSG assay.
- NLC+AMTAC 02 exhibited a modified release profile compared to pure AMTAC 02.

## Abstract

Through sonosensitizing agent activation, sonodynamic
therapy (SDT)
generates an imbalance of reactive oxygen species (ROS) that is potentially
damaging to target cells. Acridine derivatives (AD), such as AMTAC
compounds (01, 02, 18, 22), present properties of sonosensitizing
agents for use in SDT. This work aims to formulate and characterize
nanostructured lipid carriers (NLC) containing AD for the application
of SDT as a low-invasive breast cancer (BC) treatment. DLS, ELS, SOSG
assay, MTT assay, in vitro release study, and in vivo efficacy techniques were applied. DLS and ELS showed
a size range of 107.03 to 119.96 nm, zeta potential of −14.31
to −4.12 mV, and a polydispersity index of 0.17 to 0.26. The
SOSG assay demonstrated that AMTAC 02 generated the highest amount
of ROS (282%). The combination of SOSG and the MTT results, which
showed cell viability <40% for all the compounds, resulted in the
selection of AMTAC 02 to proceed with further studies. The NLC+AMTAC
02 formulation showed a modified release profile compared to pure
AMTAC 02. The in vivo assay demonstrated that the
system has a tumor inhibition potential 6 times greater than the untreated
group. The data suggested that NLC-AMTAC 02-mediated SDT could represent
a promising treatment modality for BC.